Last reviewed · How we verify
CBT101
At a glance
| Generic name | CBT101 |
|---|---|
| Sponsor | Ceres Brain Therapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects (PHASE1)
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (PHASE2)
- Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBT101 CI brief — competitive landscape report
- CBT101 updates RSS · CI watch RSS
- Ceres Brain Therapeutics portfolio CI